stephen j. schuster, md: tisagenlecleucel promising in relapsed/refractory dlbcl
Published 6 years ago • 1.5K plays • Length 8:54Download video MP4
Download video MP3
Similar videos
-
17:10
prof. stephen j. schuster, m.d.: ctl019 in r/r dlbcl – interim results interview from icml 2017
-
4:13
stephen schuster: mosunetuzumab leads to durable complete remissions in non-hodgkin lymphoma
-
1:27
real world experience of tisagenlecleucel for r/r all in the us
-
6:21
sattva s. neelapu, md: encouraging results for car t-cells in refractory dlbcl
-
5:51
updated juliet results for tisagenlecleucel in dlbcl
-
10:23
data from the juliet trial of ctl019 for relapsed or refractory diffuse large b-cell lymphoma
-
2:32
dr stephen schuster outlines car t results seen in leukemia, lymphoma, and myeloma
-
3:13
tisagenlecleucel in all: follow-up data and insights
-
4:31
viola poeschel: four or six cycles of chop in younger dlbcl patients?
-
5:51
latest results from juliet: tisagenlecleucel in adults with dlbcl
-
2:06
stephen j. schuster, md -- medical oncologist at penn medicine
-
7:14
frederick locke, md: car t-cell therapy in relapsed/refractory nhl
-
1:23
ipilimumab, nivolumab & brentuximab vedotin for r/r hodgkin lymphoma
-
1:25
bringing car t-cells to the second-line setting
-
2:04
andrei r. shustov, md interview part 1
-
5:22
car-t cell update: therapy improves outcomes for patients with b-cell lymphoma
-
3:41
first multicenter trial of car t cells shows response in dlbcl
-
4:56
catherine diefenbach: polatuzumab vedotin for follicular lymphoma
-
0:32
patient selection for ctcl